Europe amyotrophic lateral sclerosis treatment market accounted for $129.5 million in 2020 and will grow by 5.4% annually over 2020-2027 owing to the rising geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies.
Highlighted with 31 tables and 35 figures, this 86-page report “Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Europe amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Country.
Also Read: http://www.marketwatch.com/story/europe-amyotrophic-lateral-scleros...
Based on Treatment Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Medication
o Riluzole (Rilutek)
o Radicava (Edaravone)
o Tiglutik (Thickened Riluzole)
o Nuedexta
• Stem Cell Therapy
• Other Treatments
Based on ALS Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Sporadic ALS
• Familial ALS
Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
Also Read: http://www.marketwatch.com/story/retro-reflective-label-market-rese...
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included.
Also Read: http://www.marketwatch.com/story/vacuum-insulated-panel-vip-shipper...
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AB Science SA
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Biohaven Pharmaceutical Holding Co., Ltd.
BrainStorm Cell Limited
Corestem, Inc.
F.Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Also Read: http://www.marketwatch.com/story/plc-splitter-market-research-repor...
TABLE OF CONTENT :
1 Introduction 6
1.1 Industry Definition and Research Scope 6
1.1.1 Industry Definition 6
1.1.2 Research Scope 7
1.2 Research Methodology 10
1.2.1 Overview of Market Research Methodology 10
1.2.2 Market Assumption 11
1.2.3 Secondary Data 11
1.2.4 Primary Data 11
1.2.5 Data Filtration and Model Design 12
1.2.6 Market Size/Share Estimation 13
1.2.7 Research Limitations 14
1.3 Executive Summary 15
2 Market Overview and Dynamics 17
2.1 Market Size and Forecast 17
2.1.1 Impact of COVID-19 on World Economy 18
2.1.2 Impact of COVID-19 on the Market 20
2.2 Major Growth Drivers 22
2.3 Market Restraints and Challenges 26
2.4 Emerging Opportunities and Market Trends 29
2.5 Porter’s Fiver Forces Analysis 33
3 Segmentation of Europe Market by Treatment Type 37
3.1 Market Overview by Treatment Type 37
3.2 Medication 39
3.3 Stem Cell Therapy 41
3.4 Other Treatments 42
4 Segmentation of Europe Market by ALS Type 43
4.1 Market Overview by ALS Type 43
4.2 Sporadic ALS 45
4.3 Familial ALS 46
5 Segmentation of Europe Market by Distribution Channel 47
5.1 Market Overview by Distribution Channel 47
5.2 Hospital Pharmacies 49
5.3 Retail Pharmacies 50
5.4 Online Pharmacies 51
5.5 Other Distribution Channels 52
6 European Market 2020-2027 by Country 53
6.1 Overview of European Market 53
6.2 UK 56
6.3 France 58
6.4 Germany 60
6.5 Spain 62
6.6 Italy 64
6.7 Russia 66
6.8 Rest of European Market 68
7 Competitive Landscape 70
7.1 Overview of Key Vendors 70
7.2 New Product Launch, Partnership, Investment, and M&A 73
7.3 Company Profiles 74
AB Science SA 74
Amylyx Pharmaceuticals Inc. 76
Biogen Inc. 77
Biohaven Pharmaceutical Holding Co., Ltd. 78
BrainStorm Cell Limited 79
Corestem, Inc. 80
F.Hoffmann-La Roche AG 81
Ionis Pharmaceuticals, Inc. 82
Mitsubishi Tanabe Pharma Corporation 83
Otsuka Pharmaceutical Co., Ltd. 84
Sun Pharmaceutical Industries Ltd. 85
RELATED REPORTS 86
Table 1. Snapshot of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027 16 
Table 2. Growth Rate of World GDP, 2020-2022 19
Table 3. Main Product Trends and Market Opportunities in Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 29
Table 4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 37
Table 5. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, $ mn 40
Table 6. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 43
Table 7. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 47
Table 8. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 55
Table 9. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 57
Table 10. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 57
Table 11. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 57
Table 12. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 59
Table 13. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 59
Table 14. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 59
Table 15. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 61
Table 16. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 61
Table 17. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 61
Table 18. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 63
ALSO READ: http://www.marketwatch.com/story/oxidoreductases-professional-surve...
Table 19. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 63
Table 20. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 63
Table 21. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 65
Table 22. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 65
Table 23. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 65
Table 24. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 67
Table 25. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 67
Table 26. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 67
Table 27. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe by Country, 2017-2027, $ mn 69
Table 28. AB Science SA: Company Snapshot 74
Table 29. AB Science SA: Business Segmentation 74
Table 30. AB Science SA: Product Portfolio 75
Table 31. AB Science SA: Revenue, 2017-2019, $ mn 75Figure 1. Research Method Flow Chart 10
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 13
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 15
Figure 4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 17
Figure 5. Impact of COVID-19 on Business 20
Figure 6. Primary Drivers and Impact Factors of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 22
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 25
Figure 8. Primary Restraints and Impact Factors of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 26
Figure 9. Investment Opportunity Analysis 30
Figure 10. Porter’s Fiver Forces Analysis of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 33
Figure 11. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue 37
Figure 12. Contribution to Europe 2021-2027 Cumulative Revenue by Treatment Type, Value ($ mn) and Share (%) 38
Figure 13. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, $ mn 39
Figure 14. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, $ mn 41
Figure 15. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, $ mn 42
Figure 16. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue 43
Figure 17. Contribution to Europe 2021-2027 Cumulative Revenue by ALS Type, Value ($ mn) and Share (%) 44
Figure 18. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, $ mn 45
Figure 19. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, $ mn 46
Figure 20. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue 48
Figure 21. Contribution to Europe 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 48
Figure 22. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, $ mn 49
Figure 23. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, $ mn 50
Figure 24. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, $ mn 51
Figure 25. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, $ mn 52
Figure 26. Breakdown of European Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 54
Figure 27. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 55
Figure 28. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in UK, 2017-2027, $ mn 56
Figure 29. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in France, 2017-2027, $ mn 58
Figure 30. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Germany, 2017-2027, $ mn 60
Figure 31. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Spain, 2017-2027, $ mn 62
Figure 32. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Italy, 2017-2027, $ mn 64
Figure 33. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Russia, 2017-2027, $ mn 66
Figure 34. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe, 2017-2027, $ mn 68
Figure 35. Growth Stage of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period 70 …………..Continued
CONTACT DETAILS
[email protected]
+44 203 500 2763
+1 62 825 80070
971 0503084105